

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2



---

**DIAMEDICA THERAPEUTICS INC.**  
(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

- No fee required
  - Fee paid previously with preliminary materials
  - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
- 
-



DIAMEDICA THERAPEUTICS INC.  
301 CARLSON PARKWAY  
SUITE 210  
MINNEAPOLIS, MN 55305

# Your **Vote** Counts!

**DIAMEDICA THERAPEUTICS INC.**

2026 Annual General Meeting

Vote by May 19, 2026

11:59 PM Eastern Daylight Savings Time



V91592-P45804

## You invested in DIAMEDICA THERAPEUTICS INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. **This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 20, 2026.**

### Get informed before you vote

View the Notice and Proxy Statement and 2025 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 6, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit <https://materials.proxyvote.com/25253X>, (2) call 1-800-579-1639 or (3) send an email to [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com). If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit [www.ProxyVote.com](http://www.ProxyVote.com)

Control #

#### Smartphone users

Point your camera here and vote without entering a control number



#### Vote in Person at the Meeting\*

May 20, 2026  
9:00 AM CDT

301 Carlson Parkway  
Suite 210  
Minneapolis, Minnesota 55305, USA

\*Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommendations
1. To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified. <b>Nominees:</b>	
1a. Michael Giuffre, M.D.	✓ For
1b. Richard Kuntz, M.D., M.Sc.	✓ For
1c. Tanya N. Lewis	✓ For
1d. Daniel J. O'Connor	✓ For
1e. James Parsons	✓ For
1f. Rick Pauls	✓ For
1g. Charles Semba, M.D.	✓ For
2. To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.	✓ For
3. To approve, on an advisory (non-binding) basis, executive compensation.	✓ For
4. To approve an amendment and restatement of the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.	✓ For

**NOTE:** To transact such other business as may properly come before the meeting or any adjournment of the meeting.

Prefer to receive an email instead? While voting on [www.ProxyVote.com](http://www.ProxyVote.com), be sure to click "Delivery Settings".